Pfizer (PFE) Hits New 1-Year High at $42.79

Shares of Pfizer Inc. (NYSE:PFE) hit a new 52-week high during trading on Wednesday . The company traded as high as $42.79 and last traded at $42.38, with a volume of 490335 shares changing hands. The stock had previously closed at $42.45.

A number of analysts have recently commented on PFE shares. Credit Suisse Group restated a “neutral” rating and set a $39.00 target price on shares of Pfizer in a report on Friday, May 18th. BMO Capital Markets boosted their target price on shares of Pfizer from $42.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, August 1st. Morgan Stanley restated a “buy” rating and set a $43.00 target price on shares of Pfizer in a report on Monday, June 11th. Jefferies Financial Group set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday, July 31st. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $42.00 target price on shares of Pfizer in a report on Wednesday, July 11th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and an average target price of $41.89.

The company has a market capitalization of $251.87 billion, a PE ratio of 16.17, a PEG ratio of 2.03 and a beta of 0.96. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.07. The company had revenue of $13.47 billion for the quarter, compared to analysts’ expectations of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. Pfizer’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.67 EPS. equities analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 4th. Investors of record on Friday, August 3rd were paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date of this dividend was Thursday, August 2nd. Pfizer’s payout ratio is 51.32%.

In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of the company’s stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the transaction, the insider now owns 72,672 shares in the company, valued at approximately $2,979,552. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ian C. Read sold 486,753 shares of the company’s stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $37.36, for a total transaction of $18,185,092.08. Following the transaction, the chief executive officer now owns 1,145,693 shares in the company, valued at approximately $42,803,090.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 761,230 shares of company stock worth $29,054,690. 0.06% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. AXA lifted its stake in Pfizer by 9.2% during the 4th quarter. AXA now owns 5,188,453 shares of the biopharmaceutical company’s stock valued at $187,926,000 after acquiring an additional 438,040 shares during the period. Gagnon Securities LLC increased its position in shares of Pfizer by 61.1% during the 1st quarter. Gagnon Securities LLC now owns 14,708 shares of the biopharmaceutical company’s stock valued at $522,000 after purchasing an additional 5,581 shares during the last quarter. Pennsylvania Trust Co increased its position in shares of Pfizer by 10.9% during the 2nd quarter. Pennsylvania Trust Co now owns 681,255 shares of the biopharmaceutical company’s stock valued at $28,127,000 after purchasing an additional 67,151 shares during the last quarter. Peapack Gladstone Financial Corp increased its position in shares of Pfizer by 1.4% during the 1st quarter. Peapack Gladstone Financial Corp now owns 228,149 shares of the biopharmaceutical company’s stock valued at $8,097,000 after purchasing an additional 3,089 shares during the last quarter. Finally, Baxter Bros Inc. increased its position in shares of Pfizer by 61.7% during the 1st quarter. Baxter Bros Inc. now owns 21,904 shares of the biopharmaceutical company’s stock valued at $777,000 after purchasing an additional 8,356 shares during the last quarter. Institutional investors and hedge funds own 69.14% of the company’s stock.

Pfizer Company Profile (NYSE:PFE)

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Article: How is a Moving Average Calculated?

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply